Literature DB >> 35869757

[VIPR1 promoter methylation promotes transcription factor AP-2α binding to inhibit VIPR1 expression and promote hepatocellular carcinoma cell growth in vitro].

S Ning1, C He2, Z Guo1, H Zhang1, Z Mo1.   

Abstract

OBJECTIVE: To explore the transcriptional regulation mechanism and biological function of low expression of vasoactive intestinal peptide receptor 1 (VIPR1) in hepatocellular carcinoma (HCC).
METHODS: We constructed plasmids carrying wild-type VIPR1 promoter or two mutant VIPR1 promoter sequences for transfection of the HCC cell lines Hep3B and Huh7, and examined the effect of AP-2α expression on VIPR1 promoter activity using dual-luciferase reporter assay. Pyrosequencing was performed to detect the changes in VIPR1 promoter methylation level in HCC cells treated with a DNA methyltransferase inhibitor (DAC). Chromatin immunoprecipitation was used to evaluate the binding ability of AP-2α to VIPR1 promoter. Western blotting was used to assess the effect of AP-2α knockdown on VIPR1 expression and examine the differential expression of VIPR1 in the two cell lines. The effects of VIPR1 overexpression and knockdown on the proliferation, cell cycle and apoptosis of HCC cells were analyzed using CCK8 assay and flow cytometry. We also observed the growth of HCC xenograft with lentivirus-mediated over-expression of VIPR1 in nude mice.
RESULTS: Compared with the wild-type VIPR1 promoter group, co-transfection with the vector carrying two promoter mutations and the AP-2α-over-expressing plasmid obviously restored the luciferase activity in HCC cells (P < 0.05). DAC treatment of the cells significantly decreased the methylation level of VIPR1 promoter and inhibited the binding of AP-2α to VIPR1 promoter (P < 0.01). The HCC cells with AP-2α knockdown showed increased VIPR1 expression, which was lower in Huh7 cells than in Hep3B cells. VIPR1 overexpression in HCC cells caused significant cell cycle arrest in G2/M phase (P < 0.01), promoted cell apoptosis (P < 0.001), and inhibited cell proliferation (P < 0.001), while VIPR1 knockdown produced the opposite effects. In the tumor-bearing nude mice, VIPR1 overexpression in the HCC cells significantly suppressed the increase of tumor volume (P < 0.001) and weight (P < 0.05).
CONCLUSION: VIPR1 promoter methylation in HCC promotes the binding of AP-2α and inhibits VIPR1 expression, while VIPR1 overexpression causes cell cycle arrest, promotes cell apoptosis, and inhibits cell proliferation and tumor growth.

Entities:  

Keywords:  hepatocellular carcinoma; methylation; transcription factor AP-2α; tumor growth; vasoactive intestinal peptide receptor 1

Mesh:

Substances:

Year:  2022        PMID: 35869757      PMCID: PMC9308875          DOI: 10.12122/j.issn.1673-4254.2022.07.01

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  31 in total

1.  Suppression of tumorigenicity in neuroblastoma cells by upregulation of human vasoactive intestinal peptide receptor type 1.

Authors:  Douglas A Balster; M Sue O'Dorisio; Anne R Albers; Sang K Park; Stephen J Qualman
Journal:  Regul Pept       Date:  2002-11-15

2.  Impact of cytosine methylation on DNA binding specificities of human transcription factors.

Authors:  Yimeng Yin; Ekaterina Morgunova; Arttu Jolma; Eevi Kaasinen; Biswajyoti Sahu; Syed Khund-Sayeed; Pratyush K Das; Teemu Kivioja; Kashyap Dave; Fan Zhong; Kazuhiro R Nitta; Minna Taipale; Alexander Popov; Paul A Ginno; Silvia Domcke; Jian Yan; Dirk Schübeler; Charles Vinson; Jussi Taipale
Journal:  Science       Date:  2017-05-05       Impact factor: 47.728

3.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

4.  AP-2 alpha suppresses skeletal myoblast proliferation and represses fibroblast growth factor receptor 1 promoter activity.

Authors:  Darrion L Mitchell; Joseph X DiMario
Journal:  Exp Cell Res       Date:  2009-08-21       Impact factor: 3.905

5.  G Protein-coupled Receptors in Radioiodine-refractory Thyroid Cancer in the Era of Precision Medicine.

Authors:  Valentine Suteau; Valérie Seegers; Mathilde Munier; Rym Ben Boubaker; Cécile Reyes; David Gentien; Méline Wery; Anne Croué; Frédéric Illouz; Antoine Hamy; Patrice Rodien; Claire Briet
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

6.  Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2/M cell cycle arrest, apoptosis, and autophagy.

Authors:  Fuyan Xu; Huizhi Xi; Mengya Liao; Yiqian Zhang; Hongbo Ma; Mengling Wu; Qiang Xue; Hongbao Sun; Yiwen Zhang; Yong Xia
Journal:  Cancer Chemother Pharmacol       Date:  2022-01-24       Impact factor: 3.333

7.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.

Authors:  Zefang Tang; Chenwei Li; Boxi Kang; Ge Gao; Cheng Li; Zemin Zhang
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

8.  DNA hypomethylation of a transcription factor binding site within the promoter of a gout risk gene NRBP1 upregulates its expression by inhibition of TFAP2A binding.

Authors:  Zaihua Zhu; Weida Meng; Peiru Liu; Xiaoxia Zhu; Yun Liu; Hejian Zou
Journal:  Clin Epigenetics       Date:  2017-09-15       Impact factor: 6.551

9.  Analysis of expression differences of immune genes in non-small cell lung cancer based on TCGA and ImmPort data sets and the application of a prognostic model.

Authors:  Lei Sun; Zhe Zhang; Yao Yao; Wen-Ya Li; Jia Gu
Journal:  Ann Transl Med       Date:  2020-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.